Retifanlimab and Other Immune Checkpoint Inhibitors for Squamous Cell Anal Carcinoma.

MLA

Mencel, Justin, and Sheela Rao. “Retifanlimab and Other Immune Checkpoint Inhibitors for Squamous Cell Anal Carcinoma.” TouchREVIEWS in Oncology & Haematology, vol. 19, no. 1, Jan. 2023, pp. 41–45. EBSCOhost, https://doi.org/10.17925/OHR.2023.19.1.41.

APA

Mencel, J., & Rao, S. (2023). Retifanlimab and Other Immune Checkpoint Inhibitors for Squamous Cell Anal Carcinoma. TouchREVIEWS in Oncology & Haematology, 19(1), 41–45. https://doi.org/10.17925/OHR.2023.19.1.41

Chicago

Mencel, Justin, and Sheela Rao. 2023. “Retifanlimab and Other Immune Checkpoint Inhibitors for Squamous Cell Anal Carcinoma.” TouchREVIEWS in Oncology & Haematology 19 (1): 41–45. doi:10.17925/OHR.2023.19.1.41.